Regular ArticleBreast Cancer Increases Osteoclastogenesis by Secreting M-CSF and Upregulating RANKL in Stromal Cells☆
References (50)
- et al.
Histomorphometric evidence for osteoclast-mediated resorption in metastatic breast cancer
Bone
(1994) - et al.
Production and regulation of interleukin-11 by breast cancer cells
Cancer Lett.
(1998) - et al.
Macrophage colony-stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures
Blood
(1996) - et al.
Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1alpha,25-dihidroxyvitamin D3, prostaglandin E2 or parathyroid hormone in the microenvironment of bone
Biochem. Biophys. Res. Commun.
(1998) - et al.
Single-step method of RNA isolation by acid guanidium thiocyanate–phenol–chloroform extraction
Anal. Biochem.
(1987) - et al.
CSF-1 and C-FMS gene expression in human carcinoma cell lines
Biochem. Biophys. Res. Commun.
(1988) - et al.
Macrophage colony-stimulating factor increases bone resorption by osteoclasts disaggregated from human fetal long bones
Bone
(1998) - et al.
The clinical course of bone metastases from breast cancer
Br. J. Cancer
(1987) Mechanisms of bone metastasis
Cancer
(1997)Parathyroid hormone-related protein and bone disease
Cancer
(1997)
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis
J. Clin. Invest.
Cytokines and growth factors in the regulation of bone remodeling
J. Bone Miner. Res.
Osteolytic bone metastasis in breast cancer
Breast Cancer Res. Treat.
Nuclear factor κB (NF-κB), nuclear factor interleukin-6 (NFIL-6 or C/EBPβ) and nuclear factor interleukin-6β (NFIL-6-β or C/EBPδd) are not sufficient to activate the endogenous interleukin-6 gene in the human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6-expressing human breast carcinoma cell line
Eur. J. Biochem.
Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts
Br. J. Cancer
Breast cancer cells interact with osteoblasts to support osteoclast formation
Endocrinology
Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis
J. Orthoped. Res.
Bisphosphonate risedronate reduces metastatic human breast cancer burden in nude mice
Cancer Res.
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2
J. Clin. Invest.
Efficacy of pamidronate in reducing skeletal complication in patients with breast cancer and lytic bone metastasis
N. Engl. J. Med.
Reduction in new metastasis in breast cancer with adjuvant clodronate treatment
N. Engl. J. Med.
Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures
Endocrinology
Osteoblastic cells are involved in osteoclast formation
Endocrinology
Cited by (127)
Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1 signaling
2023, International ImmunopharmacologyTherapeutics targeting the metastatic breast cancer bone microenvironment
2022, Pharmacology and TherapeuticsImmune functions of osteoclasts: New insights for bone cancers
2021, Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to BedsideMicroRNA implication in therapeutic resistance and metastatic dissemination of bone-associated tumors
2021, Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to BedsidePharmacogenomics of osteonecrosis of the jaw
2019, BoneCitation Excerpt :Most cancers with metastases have high morbidity and mortality. Bone is the third common site for the metastasis that is observed in MM and many other solid cancers, such as breast, lung, and prostate cancers [30]. Previous studies have shown that cancer cells from breast and prostate are most likely to migrate to bone during late-stage of these diseases [31,32].
Sinomenine inhibits osteolysis in breast cancer by reducing IL-8/CXCR1 and c-Fos/NFATc1 signaling
2019, Pharmacological ResearchCitation Excerpt :The above results showed the different effects of SIN on breast cancer-induced osteoclastogenesis compared with RANKL-induced osteoclastogenesis. Even though MDA-MB-231 cells were highly osteolytic in nude mice in our experiments, some reports showed that MDA-MB-231 cells had no mRNA expression of RANKL [13,50]. In addition, human osteoclast formation was increased by the CM from MDA-MB-231 cells with highly osteolytic activity, and this effect could not be inhibited by adding the RANKL inhibitor [44].
- ☆
This work was supported by American Cancer Society Institutional Research Grant 271-115115911433, Arkansas Breast Cancer Research Program Grant 231-325050011101, and the FFANY/Virginia Clinton Kelley Breast Fellowship.
- 2
To whom reprint requests should be addressed at UAMS Department of Surgery, 4301 W. Markham, Slot 725, Little Rock, AR 72205.